Hepatitis C



Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab Model


Condition:   Chronic Hepatitis c
Intervention:   Drug: Direct Acting Antivirals
Sponsors:   Postgraduate Institute of Medical Education and Research;   Directorate of Health and Family Welfare, Punjab
Recruiting


Prevalence of IL28B Polymorphism in Hepatitis C Patients


Condition:   Hepatitis C
Intervention:  
Sponsor:   Changi General Hospital
Completed


Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6


Condition:   Hepatitis C Virus
Intervention:  
Sponsor:   AbbVie
Recruiting


Hepatitis C Screening in the Primary Care Setting


Condition:   Hepatitis C
Intervention:   Diagnostic Test: Hepatitis C Antibody
Sponsor:   New York Institute of Technology
Completed


Detection of Hepatitis C Infection by Oraquick Test Among Health Care Workers


Condition:   Hepatitis C
Intervention:   Other: Screening test by Oraquick test
Sponsor:   Assiut University
Not yet recruiting


Rapid Point-of-care Testing for Hepatitis C in Community Clinics (RAPID-EC)


Condition:   Hepatitis C
Interventions:   Device: OraQuick HCV Ab test;   Device: Xpert HCV viral load test
Sponsors:   Macfarlane Burnet Institute for Medical Research and Public Health Ltd;   Gilead Sciences
Recruiting



T Regulatory Cells in Hepatitis c Infected Patients


Condition:   Hepatitis C
Intervention:   Other: Flow cytometry
Sponsor:   Assiut University
Not yet recruiting


Pattern of Skin Manifestations in Chronic Hepatitis c Virus Patients Before and After Direct Acting Anti Viral Drugs


Condition:   Hepatitis C, Chronic
Intervention:  
Sponsor:   Assiut University
Not yet recruiting


Hepatitis c and Vitamin D and Iron Status


Condition:   Hepatitis C
Interventions:   Drug: Sofosbuvir 400 mg;   Drug: Daclatasvir 60 mg/day
Sponsor:   Eman Sayed Hassan Abd Allah
Not yet recruiting


Hepatitis C Treatment Study in Myanmar


Condition:   Hepatitis C
Intervention:   Drug: Sofosbuvir 400 mg
Sponsors:   Myanmar Oxford Clinical Research Unit;   Myanmar Liver foundation (MLF);   Medical Action Myanmar (MAM)
Not yet recruiting


Study of Oral Treatments for Hepatitis C


Condition:   Chronic Hepatitis C
Interventions:   Drug: sofosbuvir/ledipasvir;   Drug: ombitasvir/paritaprevir/ritonavir (Phase 1 only);   Drug: elbasvir/grazoprevir;   Drug: Dasabuvir
Sponsors:   University of Florida;   Patient-Centered Outcomes Research Institute;   Merck Sharp & Dohme Corp.;   AbbVie
Active, not recruiting


Study to Describe the Actual Situation of Hepatitis C Treatment in Brazil


Condition:   Hepatitis C Virus
Intervention:  
Sponsor:   Janssen-Cilag Ltd.
Completed


Determining the Sustained Virologic Response of Declatasvir in Egyptian Patients With Hepatitis C Virus Genotype 4


Condition:   Hepatitis C
Interventions:   Drug: Daclatasvir 60 MG Oral Tablet [Daklinza];   Drug: Sofosbuvir 400 MG Oral Tablet [Sovaldi];   Drug: Ribavirin Oral Product
Sponsors:   Zagazig University;   Cairo University
Not yet recruiting


Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection


Condition:   Hepatitis C
Intervention:   Drug: Harvoni
Sponsor:   Gilead Sciences
Completed


C Tracker, Hepatitis C, Care & Collaboration - Patient Reported Outcomes Survey Study


Condition:   Hepatitis C
Intervention:  
Sponsor:   Boston Children’s Hospital
Active, not recruiting


The Prime Study - Comparing Hepatitis C Care and Treatment in a Primary Health Care Service With a Tertiary Hospital


Condition:   Hepatitis C
Intervention:   Other: community based hepatitis C care and treatment
Sponsors:   Macfarlane Burnet Institute for Medical Research and Public Health Ltd;   St Vincent's Hospital Melbourne
Recruiting


3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study


Condition:   Hepatitis C, Chronic
Intervention:   Drug: Previous treatment in DEB025 study
Sponsor:   Novartis Pharmaceuticals
Terminated


Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis


Condition:   Hepatitis C
Interventions:   Drug: Simeprivir (SMV);   Drug: Sofosbuvir (SOF);   Drug: Ribavirin (RBV)
Sponsors:   University of Colorado, Denver;   Janssen Scientific Affairs, LLC
Active, not recruiting


Epidemiology of Hepatitis C Virus Infection Among Opioid Substituted Patients


Condition:   Hepatitis C
Intervention:  
Sponsors:   Prof. Dr. med. Jens Reimer;   Janssen-Cilag G.m.b.H
Active, not recruiting


Prevalence and Screening of Hepatitis C in Belgium in 2015


Condition:   Hepatitis C
Interventions:   Other: Questionnaire;   Procedure: HCV serology
Sponsor:   Brugmann University Hospital
Recruiting


Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients


Condition:   Chronic Hepatitis C Infection
Intervention:  
Sponsors:   Kirby Institute;   The University of New South Wales;   Merck Sharp & Dohme Corp.
Recruiting


Surveillance and Treatment of Prisoners With Hepatitis C


Condition:   Hepatitis C
Intervention:   Drug: Sofosbuvir/velpatasvir
Sponsor:   Kirby Institute
Recruiting


Staged Phase I/II Hepatitis C Prophylactic Vaccine


Condition:   Hepatitis C
Interventions:   Biological: AdCh3NSmut1;   Biological: MVA-NSmut;   Other: Placebo
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting


A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Patients.


Condition:   Hepatitis C
Interventions:   Drug: GSK2336805 10mg;   Drug: GSK2336805 30mg;   Drug: GSK2236805 100mg;   Drug: GSK2236805 200mg;   Drug: GSK2236805 10mg;   Drug: GSK2236805 dose to be determined up to 100mg;   Drug: GSK2236805 5mg;   Drug: GSK2236805 30mg
Sponsor:   GlaxoSmithKline
Completed

Refine Your Search Advanced Search